These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

852 related items for PubMed ID: 30375398

  • 21. Inhibition of lncRNA PANDAR reduces cell proliferation, cell invasion and suppresses EMT pathway in breast cancer.
    Li Y, Su X, Pan H.
    Cancer Biomark; 2019; 25(2):185-192. PubMed ID: 31104011
    [Abstract] [Full Text] [Related]

  • 22. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
    Chau WK, Ip CK, Mak AS, Lai HC, Wong AS.
    Oncogene; 2013 May 30; 32(22):2767-81. PubMed ID: 22797058
    [Abstract] [Full Text] [Related]

  • 23. An increased expression of long non-coding RNA PANDAR promotes cell proliferation and inhibits cell apoptosis in pancreatic ductal adenocarcinoma.
    Jiang Y, Feng E, Sun L, Jin W, You Y, Yao Y, Xu Y.
    Biomed Pharmacother; 2017 Nov 30; 95():685-691. PubMed ID: 28886528
    [Abstract] [Full Text] [Related]

  • 24. Functional Activation of Mutant p53 by Platinum Analogues in Cisplatin-Resistant Cells Is Dependent on Phosphorylation.
    Xie X, He G, Siddik ZH.
    Mol Cancer Res; 2017 Mar 30; 15(3):328-339. PubMed ID: 28031409
    [Abstract] [Full Text] [Related]

  • 25. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
    Mir R, Tortosa A, Martinez-Soler F, Vidal A, Condom E, Pérez-Perarnau A, Ruiz-Larroya T, Gil J, Giménez-Bonafé P.
    Int J Cancer; 2013 Apr 01; 132(7):1525-36. PubMed ID: 22961628
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells.
    Puca R, Nardinocchi L, Pistritto G, D'Orazi G.
    Gynecol Oncol; 2008 Jun 01; 109(3):403-10. PubMed ID: 18395248
    [Abstract] [Full Text] [Related]

  • 29. Sialyltransferase ST3GAL1 promotes cell migration, invasion, and TGF-β1-induced EMT and confers paclitaxel resistance in ovarian cancer.
    Wu X, Zhao J, Ruan Y, Sun L, Xu C, Jiang H.
    Cell Death Dis; 2018 Oct 30; 9(11):1102. PubMed ID: 30375371
    [Abstract] [Full Text] [Related]

  • 30. PACT cessation overcomes ovarian cancer cell chemoresistance to cisplatin by enhancing p53-mediated apoptotic pathway.
    Yang X, Zhang Q, Yang X, Zhao M, Yang T, Yao A, Tian X.
    Biochem Biophys Res Commun; 2019 Apr 16; 511(4):719-724. PubMed ID: 30827507
    [Abstract] [Full Text] [Related]

  • 31. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
    Chiu WT, Huang YF, Tsai HY, Chen CC, Chang CH, Huang SC, Hsu KF, Chou CY.
    Oncotarget; 2015 Feb 10; 6(4):2349-65. PubMed ID: 25537512
    [Abstract] [Full Text] [Related]

  • 32. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo.
    Hu S, Yu L, Li Z, Shen Y, Wang J, Cai J, Xiao L, Wang Z.
    Cancer Biol Ther; 2010 Oct 15; 10(8):788-95. PubMed ID: 20686362
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.
    Ramadoss S, Sen S, Ramachandran I, Roy S, Chaudhuri G, Farias-Eisner R.
    Oncogene; 2017 Mar 15; 36(11):1537-1545. PubMed ID: 27694900
    [Abstract] [Full Text] [Related]

  • 36. Novel role of lncRNA CHRF in cisplatin resistance of ovarian cancer is mediated by miR-10b induced EMT and STAT3 signaling.
    Tan WX, Sun G, Shangguan MY, Gui Z, Bao Y, Li YF, Jia ZH.
    Sci Rep; 2020 Sep 08; 10(1):14768. PubMed ID: 32901049
    [Abstract] [Full Text] [Related]

  • 37. Expression of the lncRNA ZFAS1 in cervical cancer and its correlation with prognosis and chemosensitivity.
    Feng LL, Shen FR, Zhou JH, Chen YG.
    Gene; 2019 May 15; 696():105-112. PubMed ID: 30738960
    [Abstract] [Full Text] [Related]

  • 38. Knockdown of Eag1 Expression by RNA Interference Increases Chemosensitivity to Cisplatin in Ovarian Cancer Cells.
    Hui C, Lan Z, Yue-li L, Li-lin H, Li-lin H.
    Reprod Sci; 2015 Dec 15; 22(12):1618-26. PubMed ID: 26079730
    [Abstract] [Full Text] [Related]

  • 39. Long noncoding RNA TUG1 promotes cisplatin resistance in ovarian cancer via upregulation of DNA polymerase eta.
    Sonobe R, Yang P, Suzuki MM, Shinjo K, Iijima K, Nishiyama N, Miyata K, Kataoka K, Kajiyama H, Kondo Y.
    Cancer Sci; 2024 Jun 15; 115(6):1910-1923. PubMed ID: 38558246
    [Abstract] [Full Text] [Related]

  • 40. Fn14 overcomes cisplatin resistance of high-grade serous ovarian cancer by promoting Mdm2-mediated p53-R248Q ubiquitination and degradation.
    Wu AY, Gu LY, Cang W, Cheng MX, Wang WJ, Di W, Huang L, Qiu LH.
    J Exp Clin Cancer Res; 2019 Apr 25; 38(1):176. PubMed ID: 31023317
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 43.